Nuvalent
Cambridge, Massachusetts, United States · Biotechnology, Healthcare, Health Care
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The company aims to overcome the limitations of existing therapies for clinically proven kinase targets. They develop innovative small molecules to address various cancer challenges. Nuvalent is advancing a robust pipeline with investigational candidates for diffe
Key facts
- Headquarters
- Cambridge, Massachusetts, United States
- Employees
- 170
- Industries
- Biotechnology, Healthcare, Health Care
- Website
- http://www.nuvalent.com/
- Company page
Recent activity at Nuvalent
- : SEC 8-K (8.01): On November 17, 2025, Nuvalent, Inc. announced positive topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer (NSCLC) from the global ALKOVE-1 Phase 1/2 clinical trial. The results suggest that neladalkib may provide a significant treatment option for this patient population, showcasing its recommended Phase 2 dose of 150 mg once daily. The data includes preliminary findings from the Phase 2 exploratory cohort for TKI-naïve patients, marking a critical step in evaluating the efficacy of the drug. This announcement has strategic implications for the company in terms of advancing its clinical development pipeline and engaging potential investors.
- : Nuvalent Promotes Jason Waters to Senior Vice President, Commercial
- : Nuvalent, Inc.
- : Nuvalent Completes $135 Million Series B Financing To Advance Portfolio Of Novel Precisely Targeted Kinase Inhibitors For Treatment-Resistant Cancers
Nuvalent funding history
| Date | Round | Amount |
|---|---|---|
| May 2021 | Venture | $135.0M |
| May 2021 | Series B | $135.0M |
Leadership
- R. James, Executive Officer, Director
- Matthew Shair, Director
- Cameron Wheeler, Director
- Robert Jackson, Director
- Joseph Pearlberg, Director
- Gary Gilliland, Director
- Andrew Hack, Director
- Alexandra Balcom, Chief Financial Officer
- Jason Waters, Vice President Of Commercial
- Alex Balcom, Executive Officer
Verified email and direct lines for Nuvalent’s decision-makers are on Fundz. See plans
Employee benefit plans
Nuvalent files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to Nuvalent
- Aquestive Therapeutics, Inc. · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Biofrontera · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Adial Pharmaceuticals · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Os Therapies · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Lipella Pharmaceuticals · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
About Nuvalent: questions and answers
What does Nuvalent do?
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The company aims to overcome the limitations of existing therapies for clinically proven kinase targets. They develop innovative small molecules to address various cancer challenges. Nuvalent is advancing a robust pipeline with investigational candidates for diffe
Where is Nuvalent headquartered?
Nuvalent is headquartered in Cambridge, Massachusetts, United States.
How many employees does Nuvalent have?
Nuvalent has about 170 employees.
Has Nuvalent raised funding?
Yes. Fundz has recorded 2 funding events for Nuvalent. The most recent, $135.0M, was in May 2021.
Who leads Nuvalent?
Jason Waters is a Vice President Of Commercial at Nuvalent.
What is the latest news on Nuvalent?
On Nov 17, 2025, SEC 8-K (8.01): On November 17, 2025, Nuvalent, Inc. announced positive topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer (NSCLC) from the global ALKOVE-1 Phase 1/2 clinical trial. The re
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy